European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
Could oritavancin be a promising alternative treatment for staphylococcal bone and joint infections? Insights from the determination of oritavancin minimum inhibitory concentrations in a collection of clinical isolates from the French National reference centre for staphylococci.
M Berrada, C Kolenda, A Tristan, F Laurent, C Dupieux
Published: 202610.1007/s10096-025-05383-3
Abstract
Oritavancin is a long-acting lipoglycopeptide with excellent bone penetration and activity against biofilm-embedded bacteria, making it a promising candidate for the treatment of bone and joint infections (BJIs). To explore its potential in this clin…
Preview only. Read the full abstract at the source